In a landmark transaction within China's booming biopharma sector, Sino Biopharmaceutical (1177.HK) has acquired LaNova Medicines, a rising star in innovative drug development. The Hong Kong-listed pharmaceutical giant announced post-market on July 15th its agreement to purchase 95.09% equity in LaNova for up to $950 million (approximately ¥6.8 billion). After deducting LaNova's estimated cash reserves of $450 million, the net transaction value settles around $500 million.
This acquisition follows Sino Biopharmaceutical's earlier strategic investment during LaNova's Series C financing, where it secured 4.91% ownership. Post-deal completion, LaNova will become a wholly-owned subsidiary, significantly bolstering Sino Biopharmaceutical's oncology portfolio. The buyer's stock has surged 140% year-to-date, closing at HK$6.37 on July 15th – a three-year peak – with its market capitalization reaching HK$119.5 billion.
LaNova's cutting-edge pipeline features multiple potential best-in-class assets, including: • LM-108: The sole CCR8 monoclonal antibody holding dual breakthrough therapy designations • LM-305: A pioneering GPRC5D-targeting ADC licensed globally to AstraZeneca • LM-299: A PD-1/VEGF bispecific antibody partnered with Merck & Co.
Notably, LaNova has secured nearly $4 billion in international licensing deals within three years. Its $600 million agreement with AstraZeneca for LM-305 included $55 million upfront, while the Merck partnership for LM-299 commanded $888 million in prepayments plus milestones, totaling $3.288 billion. Both transactions occurred during preclinical stages, underscoring the assets' therapeutic promise.
The Shanghai-based biotech, founded in 2019, currently advances seven clinical-stage candidates and nearly twenty preclinical programs across four proprietary platforms. Its pipeline targets substantial markets, including multiple myeloma (over $30 billion globally) and next-generation immuno-oncology therapies (projected above $200 billion).
Sino Biopharmaceutical Chairman Xie Qirun emphasized that LaNova's "exceptional R&D capabilities and valuable pipeline will dramatically enhance our competitive edge in global oncology innovation," particularly in lung cancer, gastrointestinal malignancies, and autoimmune disorders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.